William C Schneider

US Patent:

20030229208, Dec 11, 2003

Filed:

Mar 13, 2003

Appl. No.:

10/389155

Inventors:

Cary Queen - Los Altos CA, US
Man Co - Cupertino CA, US
William Schneider - Mountain View CA, US
Nicholas Landolfi - Milpitas CA, US
Kathleen Coelingh - San Francisco CA, US
Harold Selick - Belmont CA, US

Assignee:

Protein Design Labs, Inc. - Fremont CA

International Classification:

G01N033/53
G06F019/00
G01N033/48
G01N033/50
C07K016/18

US Classification:

530/388150, 435/007100, 702/019000

Abstract:

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

US Patent:

20040049014, Mar 11, 2004

Filed:

Mar 13, 2003

Appl. No.:

10/389417

Inventors:

Cary Queen - Los Altos CA, US
Man Co - Cupertino CA, US
William Schneider - Mountain View CA, US
Nicholas Landolfi - Milpitas CA, US
Kathleen Coelingh - San Francisco CA, US
Harold Selick - Belmont CA, US

Assignee:

Protein Design Labs, Inc. - Fremont CA

International Classification:

C07K016/44
G06G007/48
G06G007/58

US Classification:

530/388150, 703/011000

Abstract:

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

US Patent:

20040058414, Mar 25, 2004

Filed:

May 30, 2003

Appl. No.:

10/452357

Inventors:

Cary Queen - Los Altos CA, US
Man Sung Co - Cupertino CA, US
William Schneider - Mountain View CA, US
Nicholas Landolfi - Milpitas CA, US
Kathleen Coelingh - San Francisco CA, US
Harold Selick - Belmont CA, US

International Classification:

G06F019/00
G01N033/48
G01N033/50
C07K016/44

US Classification:

435/069100, 435/326000, 435/320100, 530/388150, 702/019000

Abstract:

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

US Patent:

20080160018, Jul 3, 2008

Filed:

Nov 20, 2006

Appl. No.:

11/603273

Inventors:

Cary L. Queen - Los Altos CA, US
Man Sung Co - Cupertino CA, US
William P. Schneider - Mountain View CA, US
Nicholas F. Landolfi - Milpitas CA, US
Kathleen L. Coelingh - San Francisco CA, US
Harold E. Selick - Belmont CA, US

Assignee:

PDL BioPharma, Inc. - Fremont CA

International Classification:

A61K 39/395
C07K 16/28
A61P 19/02
A61P 3/10

US Classification:

4241331, 5303873

Abstract:

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

US Patent:

56937610, Dec 2, 1997

Filed:

Jun 7, 1995

Appl. No.:

8/474040

Inventors:

Cary L. Queen - Los Altos CA
William P. Schneider - Mountain View CA
Harold E. Selick - Belmont CA

Assignee:

Protein Design Labs, Inc. - Mountain View CA

International Classification:

C07H 2104

US Classification:

536 2353

Abstract:

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e. g. , capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3. ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

US Patent:

60463104, Apr 4, 2000

Filed:

Mar 11, 1997

Appl. No.:

8/815190

Inventors:

Cary L. Queen - Los Altos CA
William P. Schneider - Los Altos CA
Maximiliano Vasquez - Palo Alto CA

Assignee:

Protein Design Labs., Inc. - Fremont CA

International Classification:

C07K 1600

US Classification:

5303917

Abstract:

Fas ligand fusion proteins comprising a polypeptide capable of specifically binding an antigen or a cell surface marker are prepared employing recombinant DNA technology for use in, e. g. , treatment of autoimmune disorders.

US Patent:

56441436, Jul 1, 1997

Filed:

May 30, 1995

Appl. No.:

8/454542

Inventors:

Michael D. Rostoker - Boulder Creek CA
Mark Schneider - San Jose CA
Nicholas F. Pasch - Pacifica CA
Abraham Yee - Santa Clara CA
William C. Schneider - Mountain View CA

Assignee:

LSI Logic Corporation - Milpitas CA

International Classification:

H01L 2906
H01L 3900

US Classification:

257 30

Abstract:

Various techniques for forming superconductive lines are described whereby superconductive lines can be formed by stamping, etching, polishing, or by rendering selected areas of a superconductive film (layer) non-superconductive. The superconductive material can be "perfected" (or optimized) after it is formed into lines (traces). In one embodiment, trenches are etched in a substrate, the trenches are filled with superconductive material, and any excess superconductive material overfilling the trenches is removed, such as by polishing. In another embodiment, superconductive lines are formed by rendering selected areas of a superconductive layer (i. e. , areas other than the desired superconductive lines) non-superconductive by "damaging" the superconductive material by laser beam heating, or by ion implantation. Superconductive lines formed according to the invention can be used to protect semiconductor devices (e. g. , transistor structures) from over-current or overheating conditions such as those caused by CMOS latch-up.

US Patent:

56937628, Dec 2, 1997

Filed:

Jun 7, 1995

Appl. No.:

8/487200

Inventors:

Cary L. Queen - Los Altos CA
Man Sung Co - Cupertino CA
William P. Schneider - Mountain View CA
Nicholas F. Landolfi - Milpitas CA
Kathleen L. Coelingh - San Francisco CA
Harold E. Selick - Belmont CA

Assignee:

Protein Design Labs, Inc. - Mountain View CA

International Classification:

A61K 39395

US Classification:

5303873

Abstract:

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e. g. , capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3. ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.